# Alisertib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/alisertib

> The next catalyst for alisertib, sponsored by PUMA BIOTECHNOLOGY, INC. (PBYI), is its topline data readout, Oct 2027 to Jan 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | alisertib |
| Codes | PB-8237, MLN8237 |
| Sponsor | PUMA BIOTECHNOLOGY, INC. (PBYI) https://sec-api.dev/companies/pbyi/catalysts |
| Indications | with her2-negative, hr-positive metastatic breast cancer, [with extensive-stage small cell lung cancer](https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer), [chemotherapy-naïve her2-negative, hormone receptor-positive metastatic breast cancer](https://sec-api.dev/indications/chemotherapy-naive-her2-negative-hormone-receptor-positive-metastatic-breast-can), [with extensive stage small cell lung cancer](https://sec-api.dev/indications/with-extensive-stage-small-cell-lung-cancer), with advanced small cell lung cancer, [Small Cell Lung Cancer ( SCLC )](https://sec-api.dev/indications/small-cell-lung-cancer-sclc), [Small Cell Lung Cancer](https://sec-api.dev/indications/small-cell-lung-cancer), Hormone Receptor Positive HER-2 Negative Breast Cancer |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Feb 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: with extensive-stage small cell lung cancer.
- First seen 2025-02-27, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035279): "In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-026282): "In February 2024, Puma initiated ALISCA®-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-015621): "In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/ex_938051.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-005869): "In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/ex_916496.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-033604): "In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/ex_858472.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-025463): "In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/ex_842991.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015514): "In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/ex_785138.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-005477): "In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/ex_783116.htm
- SEC Form 10-K (accession 0001437749-26-005891): "In February 2024 we announced that we initiated the Phase II ALISCATM-Lung1 trial." https://www.sec.gov/Archives/edgar/data/1401667/000143774926005891/pbyi20251231_10k.htm
- SEC Form 10-K (accession 0001437749-25-005496): "In February 2024 we announced that we initiated the Phase II ALISCATM-Lung1 trial." https://www.sec.gov/Archives/edgar/data/1401667/000143774925005496/pbyi20241231_10k.htm

### Nov 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: with HER2-negative, HR-positive metastatic breast cancer.
- First seen 2025-02-27, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035279): "In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-026282): "In November 2024, Puma initiated ALISCA®-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-015621): "In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926015621/ex_938051.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-26-005869): "In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926005869/ex_916496.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-033604): "In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/ex_858472.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-025463): "In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/ex_842991.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015514): "In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/ex_785138.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-005477): "In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774925005477/ex_783116.htm

### Q4 2025: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer.
- First seen 2025-05-08, last confirmed 2025-08-07.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-025463): "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (Q4 2025) and (ii) presentation of additional interim data from the ALI-4201/ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (Q4 2025)."" https://www.sec.gov/Archives/edgar/data/1401667/000143774925025463/ex_842991.htm
- Press release filed with the SEC (EX-99) (accession 0001437749-25-015514): "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H2 2025); and (ii) presentation of additional interim data from the ALI-4201/ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (H2 2025)."" https://www.sec.gov/Archives/edgar/data/1401667/000143774925015514/ex_785138.htm

### 1H 2026: interim data readout

- Status: scheduled. Date confidence: half. Stage: 2. Indication: chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer.
- First seen 2025-11-06, last confirmed 2025-11-06.
- Press release filed with the SEC (EX-99) (accession 0001437749-25-033604): "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) presentation of interim data from ALISCA™-Breast1, a Phase II trial of alisertib in combination with endocrine treatment in patients with chemotherapy-naïve HER2-negative, hormone receptor-positive metastatic breast cancer (H1 2026) and (ii) presentation of additional interim data from the ALI-4201/ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer (H1 2026)."" https://www.sec.gov/Archives/edgar/data/1401667/000143774925033604/ex_858472.htm

### Q3 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 1/2. Indication: with extensive stage small cell lung cancer.
- First seen 2026-08-06, last confirmed 2026-08-06.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-026282): "Mr. Auerbach added, "We anticipate the following key milestones over the next 12 months: (i) initiation of enrollment in ALISCA®-Lung2, a Phase I/II trial of alisertib in combination with paclitaxel for the treatment of patients with extensive stage small cell lung cancer (Q3 2026)" https://www.sec.gov/Archives/edgar/data/1401667/000143774926026282/ex_973970.htm

### Sep 2026: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: with advanced small cell lung cancer.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001437749-26-035279): "In September 2026, Puma initiated ALISCA®-Lung2, a Phase II clinical trial of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer." https://www.sec.gov/Archives/edgar/data/1401667/000143774926035279/ex_1011140.htm

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." https://clinicaltrials.gov/study/NCT06095505

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06095505 (A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." https://clinicaltrials.gov/study/NCT06095505

### Dec 2027 to Mar 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06369285 (A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." https://clinicaltrials.gov/study/NCT06369285

### December 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06369285 (A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-30 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." https://clinicaltrials.gov/study/NCT06369285

### Mar to Jun 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Small Cell Lung Cancer ( SCLC ).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." https://clinicaltrials.gov/study/NCT07465757

### March 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Small Cell Lung Cancer ( SCLC ).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." https://clinicaltrials.gov/study/NCT07465757

## Same indication

- [ABBV-706](https://sec-api.dev/pdufa/abbv-706) (ABBV)
- [Pf-07104091 monotherapy dose escalation](https://sec-api.dev/pdufa/pf-07104091-monotherapy) (PFE)
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404) (PFE)
- [IMDELLTRA® (tarlatamab)](https://sec-api.dev/pdufa/tarlatamab) (AMGN)

Calendar months: [October 2027](https://sec-api.dev/fda-calendar/2027-10), [December 2027](https://sec-api.dev/fda-calendar/2027-12), [March 2028](https://sec-api.dev/fda-calendar/2028-03)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/alisertib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Alisertib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/alisertib

```bibtex
@misc{secapidev_pdufa_alisertib_20261116,
  title        = {Alisertib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/alisertib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_alisertib_20261116","title":"Alisertib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/alisertib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
